Authored Content
New research highlights the market access risks faced by manufacturers who use less traditional outcome measures to demonstrate value of innovative hemato-oncology therapies.
Uncovering beliefs underpinning payer decision making can help global access teams achieve optimal and equitable patient access, faster.
As national reimbursement is no longer the only priority for global teams, value communication materials may evolve to enable meaningful, timely patient access.